BC Extra | May 29, 2019
Preclinical News

May 29 Preclinical Quick Takes: Vor debuts lead stem cell program; plus an inverse Alzheimer's-cancer target, and statins for cognitive defects

Vor Biopharma unveils lead candidate comprising CD33-deficient stem cells  Vor Biopharma Inc. co-founder Siddhartha Mukherjee at Columbia University showed transplantation of hematopoietic stem cells with genetic ablation of CD33 allowed CAR T or antibody therapy...
BioCentury | Dec 8, 2017
Finance

Negotiating NASH

New Enterprise Associates has signed onto Metacrine Inc.’s proposition that there is room to improve upon more advanced FXR agonists in development for non-alcoholic steatohepatitis. Metacrine closed an untranched $22 million series B round led...
BioCentury | May 9, 2016
Product Development

Community organizers

With new papers published by the day and a flurry of big-dollar deals and financings, it's hard to separate the signal from the noise in the microbiome space. The space has become so hot that...
BC Extra | Feb 3, 2016
Clinical News

Synthetic slides after dropping Trimesta for RRMS

Synthetic Biologics Inc. (NYSE-M:SYN) fell $0.21 (14%) to $1.28 on Tuesday after it said it terminated a license with the Regents of the University of California to IP covering the use of Trimesta , an oral...
BC Week In Review | Jan 25, 2016
Clinical News

SYN-010: Extension study data

Top-line data from 54 breath methane-positive IBS-C patients in the open-label extension of the double-blind, placebo-controlled, U.S. Phase II SB-2-010-001 trial showed that once-daily 42 mg oral SYN-010 met the primary endpoint of reducing breath...
BC Week In Review | Dec 21, 2015
Clinical News

SYN-010: Phase II data

Top-line data from the double-blind, placebo-controlled, U.S. Phase II SB-2-010-001 trial in 63 breath methane-positive IBS-C patients showed that once-daily 42 mg oral SYN-010 significantly reduced the area under the curve (AUC) of breath methane...
BC Week In Review | Oct 26, 2015
Clinical News

SYN-010: Phase II started

Synthetic began an open-label, U.S. Phase II extension trial to evaluate 42 mg oral SYN-010 once daily for about 2 months in about 60 patients who completed the Phase II SB-2-010-001 trial. Top-line data from...
BC Week In Review | Jul 20, 2015
Clinical News

SYN-010: Phase II started

Synthetic began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 21 and 42 mg oral SYN-010 once daily for 28 days in about 60 breath methane-positive patients. Synthetic is developing SYN-010 under section 505(b)(2)...
BC Innovations | Dec 4, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Ras/RAF/MEK/ERK pathway; Src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) Mouse studies suggest inhibiting ERK activity could help treat cognitive deficits in Noonan...
BioCentury | Dec 16, 2013
Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
Items per page:
1 - 10 of 139